<--- Back to Details
First PageDocument Content
Acute leukemia / Tumor lysis syndrome / Uric acid / Acute uric acid nephropathy / Hyperuricemia / Hematological malignancy / Myelodysplastic syndrome / Acute myeloid leukemia / Acute lymphoblastic leukemia / Medicine / Oncology / Nephrology
Acute leukemia
Tumor lysis syndrome
Uric acid
Acute uric acid nephropathy
Hyperuricemia
Hematological malignancy
Myelodysplastic syndrome
Acute myeloid leukemia
Acute lymphoblastic leukemia
Medicine
Oncology
Nephrology

An upper limit for macromolecular crowding effects

Add to Reading List

Source URL: www.biomedcentral.com

Download Document from Source Website

File Size: 224,41 KB

Share Document on Facebook

Similar Documents

The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2

DocID: 1uSbg - View Document

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

DocID: 1uJQ2 - View Document

Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling Ingrid G Winkler, PhD1*, Johanna M Erbani, PhD student2*,

DocID: 1u5Xi - View Document

Regulatory Perspective: Acute Leukemia Clinical Endpoints Nancy S. Scher, MD, FACP DODP, CDER, FDA 1

DocID: 1tdCV - View Document

· ACUTE LYMPHOBL ASTIC LEUKEMIA · Incorporating Antibodies into Treatment Strategies for Acute Lymphoblastic Leukemia Nicholas J. Short, MD, and Elias Jabbour, MD

DocID: 1shAS - View Document